CTBI
Community Trust Bancorp, Inc.
CTBI's outlook is improving, though it still trails on the overall score.
MS
Morgan Stanley
MS has the edge over CTBI overall, supported by stronger modeled upside and stronger valuation.
CTBI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CTBI's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CTBI.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
CTBI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.8x | $53.41 | -24% |
| Fair | 10x | $61.56 | -12% |
| Forward | 11x | $70.09 | — |
| Expensive | 12x | $72.83 | +3.9% |
| Current | 12x | $70.09 | — |
Historical ranges are pointers, not guarantees.
CTBI has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
CTBI Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CTBI, with profitability improving.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
CTBI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.46 | +6.3% |
| Q3 2026 | $6.08 | +18% |
| Q2 2026 | $5.97 | +18% |
| Q1 2026 | $5.71 | +19% |
| Q4 2025 | $5.43 | +18% |
| Q3 2025 | $5.17 | +17% |
| Q2 2025 | $5.08 | +17% |
| Q1 2025 | $4.79 | +11% |
| Q4 2024 | $4.61 | +5.7% |
CTBI's earnings per share have climbed steadily: $6.08 over the past year, up 18% from the year before, and higher year over year for eight quarters in a row.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over CTBI on earnings, with stronger typical year-over-year growth.
CTBI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $79.7M | +11% |
| Q2 2026 | $78.5M | +12% |
| Q1 2026 | $74.2M | +12% |
| Q4 2025 | $74.7M | +14% |
| Q3 2025 | $71.5M | +14% |
| Q2 2025 | $70.2M | +14% |
| Q1 2025 | $66.2M | +13% |
| Q4 2024 | $65.7M | +16% |
CTBI's revenue has grown year over year for 11 quarters in a row: $80M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 43% | -0.5 points |
| Q2 2026 | 49% | +2.6 points |
| Q1 2026 | 48% | +4.7 points |
| Q4 2025 | 47% | +2.7 points |
| Q3 2025 | 43% | -0.6 points |
| Q2 2025 | 46% | +3.9 points |
| Q1 2025 | 43% | +2.3 points |
| Q4 2024 | 45% | +3.6 points |
CTBI has the edge over MS on profitability, with a higher operating margin.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over CTBI on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
CTBI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.4M | -11% |
| Q2 2026 | $43.1M | +217% |
| Q1 2026 | $37.9M | +9.9% |
| Q4 2025 | $13M | -33% |
| Q3 2025 | $36.4M | +2.8% |
| Q2 2025 | $13.6M | -26% |
| Q1 2025 | $34.5M | +44% |
| Q4 2024 | $19.4M | +3.7% |
CTBI has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
CTBI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +15K shares |
| 1 year | +0.3% | +61K shares |
| 3 years | +1.2% | +210K shares |
| 5 years | +1.7% | +306K shares |
| Available history | +2.1% | +374K shares |
CTBI has 18M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $1.1M |
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over CTBI on shareholder dilution, with a more favorable share count trend.
CTBI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.3x | Net Cash |
| Q2 2026 | -3.6x | Net Cash |
| Q1 2026 | -2.6x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | -4.1x | Net Cash |
| Q2 2025 | -3.2x | Net Cash |
| Q1 2025 | -2.9x | Net Cash |
| Q4 2024 | -0.6x | Net Cash |
CTBI has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
CTBI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.8 | Neutral |
| Stochastic | 18.2 | Oversold |
CTBI's weekly RSI is 46 (neutral) and its Stochastic is 18 (oversold).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
CTBI PE vs Financial Services Sector
| Metric | CTBI | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 11% below |
| PE % | 75 | 63 | 12 pts above |
CTBI has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
CTBI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.5 | 3.3% below |
| 20 week MA | $74.8 | 6.2% below |
| 50 week MA | $67.7 | 3.6% above |
| 100 week MA | $60.4 | 16% above |
| 200 week MA | $51.4 | 36% above |
CTBI has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 36% above its 200-week average.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
CTBI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $46.5 | $37.1 | -20% |
| 2021 | $37.1 | $43.3 | +17% |
| 2022 | $43.3 | $45.7 | +5.6% |
| 2023 | $45.7 | $43.9 | -4% |
| 2024 | $43.9 | $53.6 | +22% |
| 2025 | $53.6 | $57.8 | +7.8% |
| 2026 YTD | $57.8 | $70.1 | +21% |
CTBI has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.